Researchers at Washington University have discovered a chemical compound, called Fluselenamyl, that may provide an early diagnosis of Alzheimer’s disease. Under current methods approved by the FDA, patients with Alzheimer’s typically incur a significant amount of neurological damage by the time they are diagnosed. In a press release, authors of the study say, “using this compound, I think we can reduce false negatives, potentially do a better job of identifying people in the earliest stages of Alzheimer's disease and assess the effects of treatments."